Physician profile
Maria Cisnero
NPI 1366617334
$4,888.99
in general payments reported to CMS, 2019-2025
35 companies · $562 in 2025
The $562 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $464 · 2021: $870 · 2022: $842 · 2023: $289 · 2024: $642 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,493.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $979.42 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $450.54 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.13 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $352.66 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $322.12 | 2021-2025 | Vraylar |
| Amgen INC. | $302.42 | 2019-2025 | Evenity, Prolia, Prolia |
| Sanofi-Aventis U.S. LLC | $258.56 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.93 | 2019-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $222.55 | 2019-2022 | |
| Glaxosmithkline, LLC. | $180.61 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $167.21 | 2019-2022 | |
| Amarin Pharma, INC. | $150.15 | 2019-2020 | |
| Pfizer INC. | $125.09 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $82.17 | 2019-2023 | Spravato |
| Kowa Pharmaceuticals America, INC. | $82.15 | 2022-2025 | Zoryve |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $70.95 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $62.97 | 2024-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $49.96 | 2019-2020 | |
| Horizon Therapeutics Plc | $40.10 | 2020-2022 | |
| Exact Sciences Corporation | $33.84 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $33.73 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $29.08 | 2019 | |
| Supernus Pharmaceuticals, INC. | $27.96 | 2019-2020 | |
| Redhill Biopharma INC. | $27.91 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.89 | 2021 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.97 | 2023 | Eliquis |
| Xeris Pharmaceuticals, INC. | $16.56 | 2023 | Gvoke Hypopen |
| Biogen, INC. | $15.25 | 2020 | |
| Gilead Sciences, INC. | $14.44 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.32 | 2020 | |
| Optinose US, INC. | $13.65 | 2021 | |
| Vistapharm, INC. | $12.23 | 2021 | |
| Scilex Pharmaceuticals INC. | $12.07 | 2021 | |
| Mannkind Corporation | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Cisnero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.